MedTrace Logo

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

NCT02655315 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 372

Last updated 2026-02-05

No results posted yet for this study

Summary

This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.

Conditions

  • Parkinson Disease

Interventions

DRUG

Deferiprone

15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.

DRUG

Placebo

the placebo twice daily morning and evening. The treatment lasts nine months

Sponsors & Collaborators

  • European Commission

    collaborator OTHER

  • ApoPharma

    collaborator INDUSTRY

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • David Devos, MD, PhD · University Hospital, Lille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-09
Primary Completion
2020-09-22
Completion
2020-09-22

Countries

  • Austria
  • Czechia
  • France
  • Germany
  • Netherlands
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02655315 on ClinicalTrials.gov